Dear colleague,

            I welcome your interest in our high technology drug delivery platform.

Our technologies can produce mono-dispersed and biodegradable hydrogels as well as standard formulations that are soft, injectable preparations with a huge range of applications.

MedinGel™ is well suited for a number of unstable molecules including peptides and proteins, because of the mild gel formation conditions and intra-gel environment. Along with a quality release profile, these features result in a high bioavailability of trapped peptides or proteins. Our hydrogels result from the hydration of high technology polymers. Degradation products of these tri-block PLA-PEG-PLA co-polymers are already known as GRAS products, i.e. lactic acid and polyethylene glycol.

MedinCare™ is a technology that you can use for long term deliveries of small molecules, even if they have hydrophilic or hydrophobic characteristics.

MedinHub™ is a technology that can be used for long term deliveries of compounds’ combinations in the same easy to use formulation. In some cases, compounds can be delivered with different release kinetics, leading to a better response to treatments.

Our technologies use polymers that are totally inert and have no known metabolic effects at the doses envisioned. The polymers are simple to manufacture, inexpensive, and have a long shelf life. The production of the formulations is rapid and makes use of readily available pharmaceutical manufacturing equipment with a very limited number of steps.

Your company and MedinCell will both benefit from starting feasibility studies now in view of a future collaboration. You will profit from the best systems of slow release formulations, protected by a strong intellectual property position in the USA, in Europe and Japan. MedinCell is seeking partners which already have or are working towards getting a strong competence in delivery systems, to further develop our technologies in clinical trials. We have designed a model of efficient close collaboration easy to manage, including go / no go feasibility studies for your first evaluation steps.

           The 21’s pharmaceutical century is the century of the drug delivery platforms.

           Imagine turning your bioavailability nightmares into therapeutical dreams.

            Welcome to MedinCell !

                                                                                  Dr. Anh NGUYEN, PhD
                                                                                  President of MedinCell